John Pimanda

25PUBLICATIONS

152CO-AUTHORS

Medical infection agents (incl. prions)Haematological tumoursMedical mycologyMolecular targetsEpigenetics (incl. genome methylation and epigenomics)

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (25)

Sort by Publication Date:

|May 14, 2026

PU.1 inflames lower-risk MDS.

|Apr 20, 2026

Genomic evolution and natural history of myeloproliferative neoplasms on therapy.

|Oct 08, 2025

MECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemia.

Dorien Pastoors, Marije Havermans, Roger Mulet-Lazaro

|May 13, 2025

Clinical response to azacitidine in MDS is associated with distinct DNA methylation changes in HSPCs.

Julie A I Thoms, Feng Yan, Henry R Hampton

|Oct 10, 2024

Seeing MDS through the lens of genomics.

Lachlin Vaughan, John E Pimanda

|Aug 28, 2024

TOPORS E3 ligase mediates resistance to hypomethylating agent cytotoxicity in acute myeloid leukemia cells.

Peter Truong, Sylvie Shen, Swapna Joshi

Pageof 5

Frequent Collaborators

11 joint publications

Julie A I Thoms

Ashwin Unnikrishnan

David J Curtis

Stefan K Bohlander

Jason W H Wong

Fabio Zanini

Fatemeh Vafaee

Yizhou Huang

Vashe Chandrakanthan

Christopher J Jolly

Frequent Collaborators

11 joint publications

Julie A I Thoms

5 joint publications

Ashwin Unnikrishnan

4 joint publications

David J Curtis

3 joint publications

Stefan K Bohlander